

(51) International Patent Classification:
C12N 15/81 (2006.01)(21) International Application Number:
PCT/US2009/058996(22) International Filing Date:
30 September 2009 (30.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/111,910 6 November 2008 (06.11.2008) US(71) Applicant (for all designated States except US): **TATE & LYLE TECHNOLOGY LTD** [GB/GB]; Sugar Quay, Lower Thames Street, London EC3R 6DQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARLSON, Alfred** [US/US]; 2328 Hawthorne Woods Road, Terre Haute, IN 47806 (US). **ARMENTROUT, Richard, W.** [US/US]; 4828 Forrest Trail, Decatur, IL 62521 (US). **ELLIS, Timothy, Peter** [US/US]; 61 Courtland Lane, Boxborough, MA 01719 (US).(74) Agents: **PRESTIA, Paul, F.** et al.; Ratnerprestia, P.O. Box 980, Valley Forge, PA 19482 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ENHANCED PRODUCTION AND PURIFICATION OF A NATURAL HIGH INTENSITY SWEETENER




Figure 2

(57) Abstract: Recombinant *P. pastoris* producing natural sweet proteins and methods for engineering these recombinant yeast are described. Methods for enhancing foreign protein production in yeast fermentation and improved methods for purification of foreign proteins produced in yeast fermentation are presented.

ENHANCED PRODUCTION AND PURIFICATION OF A NATURAL HIGH INTENSITY SWEETENER

BACKGROUND OF THE INVENTION

Brazzein encompasses a group of related sweet proteins extracted and purified from the fruit of the African plant, *Pentadiplandra brazzeana*. (Ming and Hellekant, *FEBS Lett.* 355: 106-108, 1994). Brazzein occurs in three naturally occurring forms, the amino acid sequences of which are known: Type I is 54 amino acids in length and has an N-terminal pyrrolidone carboxylic acid; Type II is 54 amino acids in length and has an N-terminal glutamine, and Type III is 53 amino acids in length and has an N-terminal aspartic acid (Assadi-Porter, *et al.*, *Arch. Biochem. Biophys.* 376: 252-258, 2000). In addition to the natural forms of brazzein, variants of brazzein, *i.e.*, mutated and recombinant proteins with varied sequences and properties, have been created by genetic engineering, such as those described in U.S. Pat. Nos. 5,326,580; 5,346,998; 5,527,555; 5,741,537; 7,153,535; 6,274,707 and in Jin, *et al.*, *Chemical Senses* 28: 491-498; Assadi-Porter, *et al.*, *Arch. Biochem. Biophys.* 376: 259-265, 2000; Assadi-Porter, *et al.*, *Chem. Senses* 30 (Suppl. 1): i90-i91, 2005. Brazzein is a high-intensity natural sweetener, having an excellent taste profile, 400-500 times the sweetness of sucrose, and excellent stability at low pH and high temperatures.

Described below are methods, using food-grade methodology and yeast fermentation, for enhanced production and improved purification of a natural, high-quality brazzein protein that enable the commercial production of brazzein. This unique protein has applications as a sweetener in the baking, beverage, and table-top product industries.

SUMMARY OF THE INVENTION

Disclosed is an expression vector for the production of a brazzein protein by a yeast cell comprising at least two cassettes, each cassette comprising a promoter sequence, a secretion signal sequence, a brazzein protein reading frame sequence, and a termination sequence, wherein the at least two cassettes are present in an expression vector comprising an integration sequence for integration of the cassettes into the yeast genome at a specific site.

Also disclosed is a recombinant *P. pastoris* cell comprising at least two copies of a gene construct comprising a pGAP promoter sequence, a secretion signal sequence, a brazzein Type II or Type III protein reading frame sequence, and a termination sequence, wherein the copies of the gene construct are present at a preselected integration site within the *P. pastoris* genome.

A method for producing enhanced levels of a brazzein protein is presented, comprising the steps of

- a) transforming one or more cells of *P. pastoris* with the expression vector of claim 1;
- b) growing the transformed cell or cells in a fermentation medium under aerobic conditions, wherein the transformed cells produce enhanced levels of a brazzein protein compared with cells containing only one copy of the brazzein protein gene.

A method for enhancing production of a foreign protein in recombinant *Pichia* is presented, comprising the steps of

- c) initiating a culture of the recombinant *Pichia*, under aerobic conditions,
- d) reducing oxygen levels in the culture to less than 5%, and
- e) maintaining oxygen levels in the culture at less than 5%.

A method for purifying a protein from a yeast fermentation culture is also presented, comprising the ordered steps of a) adjusting the pH of the fermentation medium above or below the isoelectric point of the protein to be purified; b) removing the cells from the pH adjusted fermentation medium; c) subjecting the cell-free fermentation medium to ion-exchange chromatography and eluting the protein as a solution; d) passing the eluted protein solution through a first membrane to remove unwanted high molecular weight solutes; and e) concentrating and diafiltering the protein permeate on a second membrane to remove low molecular weight solutes.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the construction of an expression vector for brazzein for integration into the His 4 site of the *P. pastoris* genome.

Figure 2 is a schematic diagram of a process for purifying brazzein from fermentation medium.

Figure 3 is a graph showing the production of Type II brazzein by *P. pastoris* in 10 L reactor under oxygen stress. A. Raw data. B. Data normalized to optical density.

Figure 4 is a graph showing the production of Type III brazzein by *P. pastoris* in a 10 L reactor under oxygen stress. A. Raw data. B. Data normalized to optical density.

Figure 5 is a graph showing the production of Type III brazzein by *P. pastoris* in a 1000 L reactor under oxygen stress. A. Raw data. B. Data normalized to optical density.

DETAILED DESCRIPTION OF THE INVENTION

Genetic enhancement of brazzein production

Genetic manipulation of *P. pastoris* uses a different set of techniques from those commonly used with bacteria. Foreign gene expression is engineered for stable integration by homologous recombination into specific sites in the host cell chromosome. These methods generally produce yeast cells that carry only one copy of the foreign

gene. In some instances, foreign protein expression is enhanced by serendipitous integration of multiple gene copies in the yeast chromosome (Mansur, *et al.*, *Biotech. Lett.* 27: 339-345, 2005; Sunga and Cregg, *Gene* 330: 39-47, 2004). However, this does not occur with all proteins and is unpredictable. Expression of integrated multiple gene copies depends on the toxicity of the foreign protein for the yeast, the ability of the cell to process the pre-protein, and other factors, such as those reviewed in Inan, *et al.*, *Methods in Molec. Biol.* 389: 65-75, 2007). Production of a number of foreign proteins by *Pichia* has been shown to reach a limit as the gene copy number increases, primarily because cellular mechanisms for protein secretion become saturated (Liu, *et al.*, *Appl. Environ. Microbiol* 71: 5332-5340, 2005; Dean, *et al.*, *Genome Rsch.* 11: 1095-1099, 2001; Liu, *et al.*, *Protein Expression and Purification* 30: 262-274, 2003). Therefore, it is not always possible to predict whether multi-copy integration will increase expression and secretion of a foreign protein in *Pichia* (Sreekrishna, *et al.*, *Gene* 190: 55-62, 1997).

A reference *Pichia pastoris* strain, PB3, contains one copy of an artificial gene based on the amino acid sequence of Type II brazzein and optimized for yeast codon usage. The brazzein gene is under the control of the pGAP (glyceraldehyde-3-phosphate dehydrogenase) promoter of *Pichia pastoris*, allowing constitutive expression of the brazzein gene, and downstream of a 19 amino acid pre-sequence for *S. cerevisiae* MF- α (mating factor alpha), allowing secretion of the brazzein into the yeast medium. However, this yeast strain produces brazzein at insufficient levels for efficient commercial production.

Methods are described below that enhance the production of high levels of brazzein proteins by *P. pastoris* in large scale fermentation. The terms "enhanced production," "increased production," "enhanced yield," and "increased yield" as used herein mean that the amount of brazzein measured in the final *Pichia* fermentation broth by the "enhanced" or "increased" *Pichia* yeast production strain is greater than that of the reference strain, PB3.

One embodiment of a multi-gene construct that can be used to transform *P. pastoris* for enhanced production of brazzein is shown in Figure 1A (Figure 1 depicts Type III brazzein, but the same strategy can be used for the Type II brazzein gene). *Bam* H1 gene cassettes are designed to contain, in order from 5' to 3', the *P. pastoris* pGAP promoter, the 19 amino acid *S. cerevisiae* mating factor alpha pre-sequence, either the type II or type III brazzein gene and the AOX1 terminator, as shown in Figure 1A. A small percentage of Type II brazzein is spontaneously converted to Type I brazzein in yeast fermentation cultures. However, Type I brazzein can be produced by chemically converting the N-terminal glutamine of Type II brazzein to pyroglutamate using standard methods, for example, as described in Khandke, *et al.*, *Int. J. Peptide Protein Res.* 34: 118-123, 1989 or through enzymatic conversion, for example, with the QcyclaseTM enzyme from Qiagen.

While the pGAP promoter is preferred, other *P. pastoris* constitutive or inducible promoter sequences may be used, including, but not limited to, PPHIS4, FLD1, PEX 8, YPTI, as described in Sunga and Cregg, *Gene* 330: 39-47, 2004 and Lin-Cereghino, J and Lin-Cereghino, GP, *Methods in Molecular Biology* 389: 11-25, 2007, TEF1 (Ahn, et al., *Appl. Microbiol. Biotechnol.* 74: 601-608, 2007), and PGK1 (de Almeida, et al., *Yeast* 22: 725-737, 2005; WO/1994/24280). More than one type of promoter may be used in multi-copy constructs, e.g., the pGAP promoter with PGK1. Alternatively, hybrid promoters may be created using parts of different promoters.

Any leader signal sequence (pre-, pro-, or pre-pro), from *Pichia* or other organisms, that promotes secretion of brazzein can be used, such as the full length *S. cerevisiae* MF- α or other variations of the MF- α leader sequence; matrix metalloproteinase, PHO-1 and PHA-E leader sequences; and the β -glucanase leader sequence. (Xiong et al., *Acta Biochim. Biophys. Sinica* 35: 154-160, 2003; Sreekrishna, et al., *Gene* 190: 55-62, 1997; Lin-Cereghino, J and Lin-Cereghino, GP, *Methods in Molecular Biology* 389: 11-25, 2007; US2007/0122895).

In addition to AOX1, other terminator sequences can be utilized. For an appropriate promoter, such as those listed above, the termination signal for the associated *P. pastoris* gene can be used. For example, the FLD1 promoter and terminator have been successfully used together as described by Sunga and Cregg, *Gene* 330: 39-47, 2004. Alternatively, terminator and promoter sequences from different genes may be paired in the construct.

Multimeric brazzein cassettes are prepared by ligating copies of the *Bam* H1 fragments to each other. Ligations may be replicated, screened and characterized by any appropriate method, such as those described in Example 1. Following construction, the cassettes are then cloned into an expression plasmid or other vector from which the DNA can be easily amplified. Any appropriate vector carrying a selectable marker, e.g., antibiotic resistance, may be used. For example, the cassettes can be cloned into *E. coli* plasmid vectors and *E. coli* used to produce the DNA for transforming yeast cells. In the embodiment shown in Figure 1B, ligation products with the desired number of brazzein cassettes were inserted into the *Bam* H1 site of pUC57, as described in Example 1. Alternatively, the DNA can be amplified *in vitro*, for example, as described by Dean, *Genome Res.* 11: 1095-1099, 2001, and used to transform yeast cells.

In one embodiment, an expression plasmid is created by inserting the *Pichia* histidine gene 4, PPHIS4, which includes the HIS4 reading frame, 84 base pairs of promoter sequence and 40 base pairs of terminator sequence, into the vector comprising the brazzein cassettes, (Figure 1C). PPHIS4 allows integration of the foreign gene at the chromosomal HIS 4 site of *P. pastoris*. Any *P. pastoris* gene containing appropriate restriction sites can be used as a homologous recombination site for integration. Other possible integration sites include, but are not limited to, *P. pastoris* genes pGAP, AOX1,

PHO1, and FLD1. The final expression plasmid is generally sequenced to confirm that the correct gene sequences are present.

Conventional methods of molecular biology are used to create the brazzein cassettes, plasmids, and expression vectors. Such methods are described, for example, in *Molecular cloning : a laboratory manual*, 3rd ed., Sambrook, Joseph; Russell, David W., New York: Cold Spring Harbor Laboratory, 2001; *Molecular Cloning: A laboratory manual*, 2d ed., Sambrook, J., Fritsch, E. F., and Maniatis, T. New York: Cold Spring Harbor Laboratory Press, 1989; Cold Spring Harbor Protocols, cshprotocols.cshlp.org; *Current Protocols in Molecular Biology*, currentprotocols.com.

The expression vectors are used to transform *P. pastoris*. Any appropriate method of transformation may be used including electroporation and chemical-mediated transformation as described, for example, in Cregg, *Methods in Molecular Biology* 389: 27-42, 2007 and in Becker and Guarenta, *Methods in Enzymology* 194: 182-187, 1991. Transformed yeast cells may be stored at -80° C in a solution containing 10% glycerol.

Environmental enhancement of brazzein production

The production of brazzein by *Pichia* yeast engineered to produce brazzein proteins under control of the pGAP promoter can, surprisingly, be regulated by controlling the availability of oxygen in the fermentation reactor. In general, fermentation cultures of *Pichia* are grown as fed batch cultures in 20-40% air saturation (0.04-0.09 mg/ml dissolved oxygen). As described in Examples 5 and 6 and shown in Figures 2-4, restricting available O₂ to less than about 5% air saturation causes a 2 - 2.5 fold increase in production and secretion of brazzein Type II (Figure 2) and Type III (Figures 3 and 4).

No differences were observed in optical density (*i.e.*, cell proliferation), CO₂ evolution, O₂ uptake, or glucose consumption between the control and oxygen stressed cultures. The yeast continue to grow aerobically in the low O₂ environment, and no changes in cell metabolism other than enhanced production of brazzein were observed. Although the exact mechanism for the oxygen stress effect is not known, it appears to have a specific effect on the synthesis of the foreign proteins. Secretion of the foreign proteins occurs at a maximal rate even at normal oxygen levels, as evidenced by the lack of accumulation of these proteins inside the yeast cells. While not excluding other hypotheses, it appears that oxygen stress affects the function of the pGAP promoter in *Pichia*. Therefore, the oxygen stress technique can be used to increase *Pichia* production of any foreign protein that is controlled by the pGAP promoter. Other promoters are likely to be stimulated by oxygen stress.

Pichia is one of the best organisms for large-scale production of foreign proteins, and genetic methods to enhance the production of foreign proteins in *Pichia* have been widely studied and are reviewed in Cregg, *Methods in Mol. Biol.* 389: 1-7, 2007. The

pGAP promoter is a constitutive promoter native to *Pichia*. Standard methods of molecular biology, such as those described above and in Examples 1 - 4, may be used to clone a foreign protein with the pGAP promoter in an appropriate expression vector for production and secretion of the foreign protein under control of the pGAP promoter.

5 *Pichia* cells are then transformed with the expression vector using any suitable method of transformation and grown in a fed-batch culture, such as that described in Example 5. Other methods of culture that avoid the production of ethanol may also be used, for example, a simple batch culture with glycerol as the food source, or a chemostat culture system. The yeast culture is usually maintained and fed until an upper limit of cell
10 density corresponding to a wet (packed) cell volume that is 60% of the total fermentation volume is achieved.

Oxygen stress of the culture can be initiated at any time. Oxygen stress can be initiated by any means that maintains O₂ availability in the culture at less than 5%. In one embodiment, described in Example 5, oxygen stress was initiated during the last
15 feed and was achieved by controlling the agitation speed of the culture. Oxygen availability can also be reduced by limiting the flow of air, manipulating the composition of the gas, altering the backpressure on the reactor, or, to some extent, by altering the feed rate of glucose.

Enhanced purification of secreted proteins from large-scale fermentation broth

20 High yields of purified protein can be obtained from large-scale yeast fermentations by following a series of ordered steps, which are shown schematically in Figure 2. The process may be scaled to any size, so it can be used for any fermentation volume, and is suitable for any protein. *Pichia* is a preferred organism for production and secretion of foreign proteins into fermentation medium. *Pichia* will grow in a minimal
25 salt medium, allowing filtration and chromatography at low conductivity. In addition, *Pichia* does not naturally secrete small proteins into the medium. Therefore, the only protein present in the medium in significant amounts will be the foreign protein to be purified and purification procedures can be optimized for that particular protein. One advantage of the process is that it does not utilize harsh chemical steps and can be
30 employed in food production.

The first step of the process is performed before the yeast cells are removed from the broth. The pH of the fermentation medium is adjusted to create either a positive or negative charge on the protein to be purified. Thus, the pH of the medium will be below or above the isoelectric point (pI) of the protein for a positive or negative charge,
35 respectively. Adjusting the pH as a first step reduces the need to dilute the micropermeate, thereby reducing the volume of material to be processed later through the ultrafiltration membrane. The second step is to remove the cells from the medium. This may be accomplished by any appropriate method including centrifugation,

clarification, and microfiltration through filters with various pore sizes. For microfiltration processes, flux rates can be regulated to match the rate of flow through the chromatography column directly downstream of the membrane.

The permeate generated by microfiltration is pumped directly to a chromatography column. Any size column can be used and size selection is based on parameters known in the art, such as volume of permeate, capacity of column resin, rate, number of load-unload cycles desired, etc. Flow rate can be regulated by a feed pump that feeds the column, thereby also limiting the permeate flow rate from the microfiltration membrane. Any cation or anion exchange resin with a high capacity for the protein of interest at the pH of the permeate can be used. As the permeate runs through the column, the protein to be purified binds to the exchange resin while nucleic acids and polymers, carbohydrates, and most other proteins that may be in the cell broth pass through the column. When a sufficient volume of permeate has been generated, the feed of permeate to the chromatography column is stopped and the column is washed with several volumes of low salt buffer at a pH approximately that of the permeate to remove residual permeate from the column without removing bound protein. The column is then washed with several volumes of salt buffer having an intermediate molarity, *e.g.*, 0.25-0.35M NaCl in 0.05 M acetate, at a pH approximately that of the permeate to remove bound proteins that are not the protein to be purified. After the washing steps, the column is eluted with a high salt buffer at a pH approximately that of the permeate to remove the bound protein to be purified. In lieu of a high salt elution buffer, the pH of the buffer can be raised or lowered to reverse the charge on the bound protein and release it from the resin. Wash and elution buffers and other column chromatography parameters can be optimized for specific proteins by methods known in the art, *e.g.*, as described in *Ion Exchange Chromatography & Chromatofocusing: Principles and Methods*, GE Healthcare, [www.4.gelifesciences.com/aptrix/upp00919.nsf/Content/71857706466D1AB8C1256EB40041805D/\\$file/11000421AA.pdf](http://www.4.gelifesciences.com/aptrix/upp00919.nsf/Content/71857706466D1AB8C1256EB40041805D/$file/11000421AA.pdf) (2004). The chromatography process removes most of the waste compounds generated during fermentation. This allows the subsequent ultrafiltration steps to run faster and minimizes the passage of contaminants into the ultrafiltration permeate.

The eluate is collected in fractions until all of the bound protein has been eluted. The process may be varied by using multiple columns, a simulated moving bed, or any appropriate modification. Fractions are assayed for protein according to known methods, *e.g.*, absorbance at 280 nm, and fractions containing protein can be pooled for further purification. The pH of the protein-containing fractions may optionally be adjusted to a pH close to the pI of the protein to facilitate ultrafiltration at this step.

The protein fractions are next passed through a 5 to 30 kD nominal molecular weight cut-off (NMWCO) ultrafiltration membrane with a high volume of reverse osmosis

purified (RO) water to remove co-eluted *Pichia* proteins. Any type of ultrafiltration membrane may be used. Such diafiltration methods and methods for optimizing diafiltration parameters are known in the art, e.g., as described in Technical Report PN33289, Pall Life Sciences, pall.com/pdf/02.0629_Buffer_Exchange_STR.pdf).

5 Following this first ultrafiltration step, the permeate is concentrated and diafiltered with a low NMWCO membrane, in general, 1kD or less NMWCO. The protein is retained and salts and other low molecular weight contaminants pass through the membrane. The concentrated protein solution can then be diafiltered with water or buffers, if desired, to adjust the salt concentration in the concentrated solution. It may
10 be desirable to again adjust the pH of the permeate prior to concentration to maintain high flux through the membrane and to prevent protein precipitation in the concentrated solution, as described in Example 9.

 If desired, the concentrated solution of purified protein may be dried by any appropriate means such as oven drying, spray drying, and freeze drying for storage as a
15 dry product.

 In one embodiment of the process, the protein to be purified is brazzein. An exemplary process for purifying types I, II, and III brazzein is described in detail in Examples 7-9. For types I, II, and III brazzein, the pH of the fermentation medium is adjusted to 3.7-3.9 prior to removal of the yeast cells. A sample of the broth is assayed
20 to estimate the concentration of protein in the broth. The fermentation broth is then pumped through a 2 m² microfiltration membrane (0.22 µm), at a rate appropriate for the estimated protein concentration, to remove cells. The permeate is then directly fed to a cation-exchange chromatography column. After completion of permeate input, the column is washed with a no salt and then low salt acetate buffer, pH about 3.8. Brazzein
25 is eluted from the column with a high salt (1M NaCl), acetate (0.05 M) buffer, pH about 3.8. Following the chromatography step, the brazzein proteins are about 95% pure.

 In this embodiment, the pH of the brazzein-containing fractions is adjusted to approximately 6.0-6.2 prior to concentration and ultrafiltration. A 10kD NMWCO PES (polyethersulfone) filter is used to concentrate the volume of the brazzein-containing
30 fractions. PES filters are preferred, because they do not exhibit changes in porosity, are easily cleaned and can be heat-sterilized. The solution is diafiltered to remove salts and buffer ions and the permeate is then concentrated and diafiltered a second time to flush the remainder of the brazzein through the membrane. The permeate is then concentrated with a 1 kD NMWCO PES filter which is then flushed with purified water.
35 For Type III brazzein, the permeate from the 10kD filter is adjusted to pH about 4.0 before concentration and filtration through the 1 kD filter membrane to prevent protein precipitation in the final concentrate. A fermentation volume of 620 L containing a mixture of Types I and II brazzein (about 280 g) yielded 4 L of solution containing about 260 g brazzein at 98% purity at the end of the purification process (Examples 7 and 8).

For Type III brazzein, a fermentation volume of 600 L containing about 126 g of brazzein yielded 2 L containing about 99 g of Type III brazzein at 98% purity (Example 9). The final solution can be dried or filter-sterilized and stored as a solution.

Examples

5 1. Construction of a multi-cassette expression vector for enhanced expression of brazzein

Bam H1 brazzein gene cassettes were designed to comprise, in order from 5' to 3', the *P. pastoris* pGAP promoter (SEQ ID NO:1), the 19 amino acid *S. cerevisiae* alpha mating factor pre-sequence (SEQ ID NO:2), either the type II (SEQ ID NO:3 (includes stop codon)) or type III (SEQ ID NO:4) brazzein gene and the AOX1 terminator (SEQ ID NO:5), as shown in Figure 1A. The brazzein cassettes were chemically synthesized and cloned into pUC57 by Integrated DNA Technologies, Coralville, IA.

Multimeric brazzein cassettes were prepared by excising the *Bam* H1 fragment by digestion with *Bam* H1, gel purifying the fragment, and ligating copies of the *Bam* H1 fragment to each other. The ligation reaction was purified and cloned into *Bam*H1 linearized, dephosphorylated pUC57 using standard techniques of molecular biology. The resulting pUC57 vector (Figure 1B) was used to transform stb14 *E. coli* cells (Invitrogen). Transformants were identified on X-gal/IPTG spread LB+ampicillin plates by blue/white color selection. Positive colonies were confirmed by restriction digests of miniprep cultures. Because *Eco*RI and *Sa*I cut to the outside of the *Bam*HI sites, and *Eco*RI/*Sa*I digest can be used to determine the number of brazzein copies present. *Bgl*II cuts near the 3' end of brazzein and a *Bgl*II digest can be used to determine the orientation of the cassettes relative to each other. Results suggest that only head-to-tail repeats are tolerated by the Stb14 cells. The brazzein cassettes were sequenced to verify that the correct sequences were present.

To produce an expression plasmid, the *Pichia* histidine gene 4, PPHIS4, (SEQ ID NO: 6), which includes the HIS4 reading frame, 84 base pairs of promoter sequence and 40 base pairs of terminator sequence was cloned into the pUC57/Brazzein cassette construct (Figure 1C).

An expression plasmid was produced for Type II brazzein with 4 copies of the brazzein Type II cassette. A Type III brazzein plasmid was produced with 2 copies of brazzein Type III cassette. Expression plasmids with greater numbers of copies of either the Type II or Type III brazzein gene could be made by ligating additional copies of the *Bam* H1 cassette together and inserting them collectively into a vector for yeast transformation.

2. Transformation of *P. pastoris* with brazzein expression plasmids

P. pastoris cells were transformed with the Type II or Type III brazzein expression plasmids of Example 1 via electroporation. Plasmids were cut with NheI to target insertion to the HIS4 site. Aliquots (40 µl) of competent *P. pastoris* cells suspended ice-cold 1M sorbitol were incubated with 10 µg of linearized plasmid DNA in an ice-cold 0.2 cm electroporation cuvette for 5 min on ice. Electroporation was performed using the following parameters: 25 µF, 200 Ω, 2000 v. Immediately following electroporation, 1 mL of ice-cold 1M sorbitol was added and the contents transferred to a sterile 10 mL tube. The tube was incubated at 30° C for 2 h then aliquots were spread onto BMDS plates (100 mM potassium phosphate, pH 6.0, 1.34% yeast nitrogen base without amino acids, 0.5% ammonium sulfate, 4 x 10⁻⁵% biotin, 1M sorbitol, 2% dextrose, 2% agar). Plates were incubated for 4-5 days at 30° C.

In some instances, chemical transformation of *Pichia* was carried out using a commercial yeast transformation kit (EZ Yeast Transformation Kit, Zymo Research) according to manufacturer's instructions.

3. Identification of transformed *P. pastoris*

Yeast colonies from Example 2 were grown for 48 h in 10 mL of YPD (yeast extract, peptone, dextrose) medium and transformants were identified by dot-blotting. Culture medium was centrifuged to remove cells and cell-free aliquots (2 µl) of full-strength and diluted (1:10) medium from each colony were blotted adjacent to each other onto a nitrocellulose membrane using a dot-blot filter apparatus. The membrane was blocked for 30 min with "blocking solution," (Western Breeze kit, Invitrogen). The membrane was then washed twice with water and incubated for 1 h in a 1:100,000 dilution of primary antibody (rabbit-anti-brazzein) capable of detecting Types I-III of brazzein in blocking medium. Following incubation with primary antibody, the membrane was then washed three times with "washing solution," (Western Breeze kit, Invitrogen), and incubated with a 1:10,000 dilution of secondary antibody (goat-anti-rabbit-HRP, Jackson Labs) for 30 min at room temperature. The membrane was subsequently washed three times with the washing solution and twice with water. A chromogenic substrate solution, (Western Breeze kit, Invitrogen), was applied to the membrane and incubated until a purple color developed (1-60 min). The membrane was again washed twice in water, air dried, and examined visually. Medium from colonies of yeast carrying multiple copies of the brazzein genes contained a noticeably higher amount of brazzein compared with the reference strain grown under identical conditions.

These results were confirmed and quantified by gel electrophoresis and HPLC. HPLC results for high-producing colonies are shown in Table 1.

4. Production of brazzein proteins by recombinant *P. pastoris*

The transformed yeast of Example 3 were cultured in 1 L stir-tank reactors using a fed batch system with medium comprising basal salts and dextrose for about 60 h. Fermentation medium was analyzed for brazzein content by polyacrylamide gel electrophoresis and HPLC analysis. Cells were removed from the broth samples by centrifugation (3,000 x g, 10 min, room temperature). The supernatant was diluted, filtered, and applied to a cationic HPLC column. The integrated peak eluting with an authentic brazzein sample was converted to mg/L using a standard of pure brazzein of known concentration. Results from the HPLC analysis are shown in Table 1. "Fold increase" is increase relative to the PB3 reference strain grown under the same conditions. The data show that the yeast with four copies of the Type II brazzein construct each secreted over four-fold greater amounts of Type II brazzein into the fermentation medium than the reference strain, PB3.

Table 1
Amount of Type II brazzein secreted into fermentation medium
by recombinant *P. pastoris*

Sample	mg/L Brazzein	Fold increase
PB3	82.7	
PB3 duplicate	87.9	
PB3 duplicate	75.9	
<i>Average PB3</i>	<i>82.0</i>	<i>1.0</i>
Type II 4x clone 2	198.3	
Type II 4x clone 5	311.1	
Type II 4x clone 8	507.2	
<i>Average Type II 4x clone</i>	<i>338.9</i>	<i>4.1</i>

5. Enhanced production of brazzein by recombinant *P. pastoris*

Recombinant *P. pastoris* capable of expressing and secreting brazzein proteins were created as described in examples 1-4, and grown as high density, fed batch fermentation cultures. The recombinant yeast were added to a minimal yeast fermentation medium comprising glucose as the sole food source. Two, 10 L fermentation reactors were prepared by adding 1 L of 10X salts buffer containing 120g/L of phosphoric acid and 25 g/L of K₂SO₄, to 6.5 L of reverse osmosis purified (RO) water. The reactor and contents were sterilized at 121°C for 30 min. A sterile solution

containing 2050 mL of 72% dissolved solids as 95% dextrose, 250 mL of a 500g/L $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ solution, and 200 mL of trace metals with biotin was prepared. This solution (25 mL) was added to each fermentation tank, and the pH was adjusted to pH 5.6 with 28% NH_4OH .

Each reactor was inoculated with 100 mL of an overnight culture (O.D. ~ 5) of the recombinant *Pichia* cells. The yeast cells were allowed to grow overnight (about 16h) until glucose in the medium was completely consumed. The medium was maintained at pH 5.6 and 30% air saturation (regulated by stirring).

The dextrose feed solution was pumped into the reactor at increasing rates (adjusted every 4 hours) until about 1 L had been added to each reactor (about 48 h). A sample was then taken from each reactor and brazzein levels in the medium were measured. The sample was filtered through a 0.22 μm filter and assayed on HPLC by ion exchange chromatography. The feed rate of the culture was increased to a final value of about 100 ml/h. This rate was continued until the culture was terminated (about 16h).

In the "control" reactor the oxygen level was maintained at 30% by regulating the stirring rate. Table 2 lists the approximate feed and agitation rates over time for a 60h, 10 L, control culture. In the "oxygen stress" reactor the agitation speed was locked at 750 RPM after reaching that rate of speed (Steps 7-8 of Table 2). In the oxygen stress reactor, oxygen levels dropped to as low as 3% during the last phase of the culture. Respiratory quotient was elevated about 5% under oxygen stress. Only minor differences were observed in optical density, CO_2 evolution, O_2 uptake, or consumption of base between the control and oxygen stress reactors.

Table 2

Simulated exponential fed batch culture for 10L final volume process

Step #	Feeding rate	EFT	Duration	RPM required	OD typical
	cc/hr	hrs	hours	(typical)	@ 660 nm
0	0	0 - 16	16	150	2.5
1	5	16-20	4	250	4.2
2	8	20-24	4	280	7
3	12	24-28	4	320	12.6
4	18	28-32	4	350	20.6
5	30	32-36	4	450	31.3
6	48	36-40	4	550	54
7	80	40-44	4	700	82
8	100	44-60	16	1000	210

EFT - elapsed fermentation time

After all the glucose feed (2500 mL) had been added, samples of the medium were again taken and analyzed as described above to quantify brazzein in the cell-free broth. Results for cultures of *Pichia* expressing Type II brazzein are shown in Figure 3 and for Type III brazzein in Figures 4 and 5. The amounts of Type II or Type III brazzein

did not differ between the control and oxygen stressed reactors at 48h, at which time conditions in each reactor were about the same. However, at the end of the culture (about 60h), the amount of Type II brazzein in the oxygen stress reactor ($\sim 3\% \text{ O}_2$) was approximately twice the amount of Type II brazzein in the control reactor ($\sim 30\% \text{ O}_2$) as shown in Figure 3A. On a per cell basis, *Pichia* cells produced about 2.2 times more Type II brazzein under oxygen stress conditions (Figure 3B).

Similar results were obtained for *Pichia* producing Type III brazzein. Oxygen stressed reactors contained approximately twice the amount of Type III brazzein as the control reactors as shown in Figure 4A. On a per cell basis, *Pichia* cells produced about 2.1 times more Type III brazzein under oxygen stress conditions (Figure 4B).

6. Effect of oxygen stress on brazzein production in commercial scale fermentation

The experiment described in the previous example was performed in a 1000 L fermentation reactor, i.e., a 100-fold scale-up of the process, with *Pichia* engineered to produce Type III brazzein. The reactors were maintained at $30\% \text{ O}_2$ until 100 L of glucose had been added (agitation rate of about 250 RPM). At this time, the agitation rate was regulated to maintain O_2 at about 3% for the remainder of the culture. As shown in Figure 5A, approximately 2.5 times more Type III brazzein was produced under oxygen stress conditions. Figure 5B shows that this effect is due to increased *Pichia* productivity, as per cell production of Type III brazzein also increased about 2.5 fold.

7. Initial purification of Type I and Type II brazzein from fermentation medium

A 1000 L fermentation of *P. pastoris* carrying 4 copies of the type II brazzein gene was carried out as described in Example 5, but with MgSO_4 reduced by a factor of 5, at 30% dissolved oxygen. The pH of the medium was allowed to drop and was then maintained at 3.7 -3.9 by addition of 12 N HCl. A sample of medium was filtered through a $0.22 \mu\text{m}$ filter and assayed by ion exchange HPLC. Peak areas corresponding to both Type II and Type I brazzein were found, as about 25% of Type II brazzein is, in general, spontaneously converted to Type I brazzein during culture. The titer of total brazzein protein was estimated to be about 0.45 g/L of cell free broth. This estimate extrapolates to an estimated 280g total brazzein in the fermentation.

Whole cell broth was pumped out of the reactor into a 2 m^2 microfiltration membrane ($0.22 \mu\text{m}$, Millipore Duro pore membrane) at a feed rate of about 45 LPM with a centrifugal pump. The feed pressure was about 37 psig and the retentate pressure was about 16 psig. Retentate was recycled back to the reactor. The permeate was pumped to a Waters Quickscale column containing 5 L Toyopearl SP550C (Tosoh Bioscience) cation-exchange chromatography column at 1 LPM. After about 8h the permeate input to the column was stopped and the column was first washed with four volumes (20 L) of

0.005M acetate buffer, pH 3.8 (+/- 0.1), and then washed with 20 L of 0.25 M NaCl in 0.05 M acetate buffer, pH 3.8. After washing, the column was eluted with 20 L of 1 M NaCl in 0.05 M acetate buffer, pH 3.8. Eluate was collected in 1 L fractions and each was assayed for brazzein. The column was flushed with eluting buffer and then washed with RO water. Significant amounts of brazzein were found only in the first 11 liters of eluate, and peak levels were found at 10 liters. The results of the assays are shown in Table 3. A total of 160-170g of brazzein was collected. Type I brazzein eluted early and later fractions contained primarily Type II brazzein.

Table 3**First elution of brazzein from ion-exchange column**

Fraction Number	Elution Volume (Liters)	Brazzein Concentration (grams/Liter)
1	4	2.1
2	5	18.0
3	6	17.9
4	7	19.3
5	8	22.4
6	9	27.9
7	10	31.7
8	11	28.7
9	12	9.0
10	13	2.0
11	14	0.5

The permeate line was reconnected to the column and the process was continued for another 12 h. The column was washed and eluted as described above and an additional 8 L of eluate containing brazzein were collected. An additional 110-120g brazzein was collected (Table 4). The brazzein collected from the column in both elutions was about 95% pure as determined by absorbance at 280 nm.

Table 4**Second elution of brazzein from ion-exchange column**

Fraction Number	Elution Volume (Liters)	Brazzein Concentration (grams/Liter)
1	3	1.3
2	4	19.2
3	5	66.8
4	6	25.5
5	7	1.8
6	8	0.4
7	9	0.3
8	10	0.2

8. Further purification of Type I and Type II brazzein

The purified brazzein from Example 7 was subjected to a two-step filtration process to remove salts and buffer ions. First, fractions were pooled to yield batches containing approximately 60-80g of brazzein. The pH of each batch was adjusted with 1 N NaOH to 6.0-6.2. A 10 kD PES filter, operating at 30-40 psid, was then used to concentrate the volume of solution to about 2.5 L. The solution was then diafiltered with 20 L of RO water and the permeate collected. The permeate was again concentrated and diafiltered to flush the remainder of the brazzein through the membrane and into the permeate. Little or no brazzein was found in the retentate.

The permeate was concentrated to 500 mL with a 1 kD PES filter cartridge and the system was flushed with 500 mL of RO water. Samples were assayed for brazzein. In general, less than 5% of the brazzein was lost to the 1 kD permeate and 95% was recovered in the retentate. The complete purification process and results are summarized in Table 5. A final yield of approximately 260 g of brazzein was recovered at 98% purity.

Table 5
Type I and II Brazzein yields through purification process

Step	Concentration	Amount	Purity	Volume
Fermentation	0.45 g/L	280 g	<10%	620 L
Column Elution	14.00 g/L	280 g	95%	20 L
10 kD permeate	2.00 g/L	280 g	98%	140 L
1 kD concentrate	65.00 g/L	260 g	98%	4 L

9. Purification of Type III brazzein from recombinant *P. pastoris*

The purification process described in Examples 7 and 8 was carried out with 1000 L fermentation medium from a culture of *P. pastoris* carrying two copies of the gene for Type III brazzein. At the end of the fermentation, the pH of the medium was adjusted to about 3.8. An assay of a filtered sample of the medium indicated that the reactor contained about 126 g of brazzein. The medium was passed through a 2 m² microfiltration cartridge as described above, but at a permeate rate of about 1 LPM. The flow rate of permeate was maintained for about 22 h.

The permeate was passed directly through a 5 L column of SP 550C resin. The column was then washed and eluted as described in Example 7, but the NaCl concentration in the second wash buffer was 0.35 M instead of 0.25 M. Eluate was collected in 1 L bottles and assayed by A280 for total protein and by HPLC for brazzein.

Elution samples were adjusted to pH 6.1 (+/-0.1) with 1 N NaOH. Two groups of 6 bottles each were processed through a 10 kD NMWCO PES filter and diafiltered with about 40 L of RO water in two steps to produce a permeate containing substantially all of

the brazzein. This permeate was collected from the membrane, adjusted to pH 4.0 (+/- 0.2) using 1 N HCl, concentrated to 1 L using a 1 kD membrane, and subsequently diafiltered with about 10 L RO water. Diafiltration was continued until conductivity reached about 250 μ S/cm or less. The solution was then allowed to concentrate to about 500 mL and the system was flushed with 500 mL of RO water. The liquid product was freeze dried to below 5% moisture. The results of this purification are shown in Table 6. Final yield was 2 L containing approximately 99 g of 98% pure Type III brazzein.

Table 6**Type III Brazzein yields through purification process**

Step	Concentration	Amount	Purity	Volume
Fermentation	0.21 g/L	126 g	<10%	600 L
Column Elution	10 g/L	120 g	95%	12 L
10 kD permeate	1.25 g/L	100 g	98%	80 L
1 kD concentrate	49 g/L	99 g	98%	2 L

Although the invention is illustrated and described herein with reference to specific embodiments, the invention is not intended to be limited to the details shown. Rather, various modifications may be made in the details within the scope and range of equivalents of the claims and without departing from the invention.

What is Claimed:

1. An expression vector for the production of a brazzein protein by a yeast cell comprising at least two cassettes, each cassette comprising a promoter sequence, a secretion signal sequence, a brazzein protein reading frame sequence, and a termination sequence, wherein the at least two cassettes are present in an expression vector comprising an integration sequence for integration of the cassettes into the yeast genome at a specific site.
2. A yeast cell comprising the expression vector of claim 1.
3. The yeast cell of claim 2, wherein the yeast cell is of the genus *Pichia*.
4. The expression vector of claim 1, wherein the brazzein protein reading frame sequence is a reading frame sequence of brazzein Type II or brazzein Type III.
5. The expression vector of claim 1, wherein the promoter is a constitutive promoter.
6. The expression vector of claim 1, wherein the promoter is the pGAP promoter.
7. The expression vector of claim 1, wherein the promoter is selected from the group of promoters consisting of PPHis4, FLD1, PEX8, YPTI, TEF1, and PGK1.
8. The expression vector of claim 1, wherein the promoter and terminator are from the same gene.
9. The expression vector of claim 1, wherein the terminator is AOX1, pGAP, or FLD1.
10. The expression vector of claim 1, wherein the secretion signal sequence is selected from the group consisting of the *S. cerevisiae* mating factor alpha signal sequence, a truncated form of the *S. cerevisiae* mating factor alpha signal sequence, the PHO-1 signal sequence, the PHA-E signal sequence, a matrix metalloproteinase signal sequence, and the beta-glucanase signal sequence.
11. A recombinant *P. pastoris* cell comprising at least two copies of a gene construct comprising a pGAP promoter sequence, a secretion signal sequence, a brazzein Type II or Type III protein reading frame sequence, and a termination sequence, wherein the copies of the gene construct are present at a preselected integration site within the *P. pastoris* genome.

12. A method for producing enhanced levels of a brazzein protein comprising the steps of
a) transforming one or more cells of *P. pastoris* with the expression vector of claim 1;
and b) growing the transformed cell or cells in a fermentation medium under aerobic conditions, wherein the transformed cells produce enhanced levels of a brazzein protein compared with cells containing only one copy of the brazzein protein gene.
13. The method of claim 12, wherein the transformed cell or cells are grown as a fed-batch fermentation culture.
14. The method of claim 12, wherein the transformed cells produce a protein selected from the group consisting of Type I brazzein, Type II brazzein, and Type III brazzein.
15. The method of claim 12, wherein the transformed cells produce a variant of a Type I, II, or III brazzein protein.
16. A method for enhancing production of a foreign protein in recombinant *Pichia* comprising the steps of a) initiating a culture of the recombinant *Pichia*, under aerobic conditions, b) reducing oxygen levels in the culture to less than 5%, and c) maintaining oxygen levels in the culture at less than 5%.
17. The method of claim 16, wherein the culture is a fed-batch fermentation culture.
18. The method of claim 16, wherein the culture is a batch culture or a chemostat culture.
19. The method of claim 16, wherein the oxygen levels in the culture are reduced and maintained by regulating the agitation speed of the culture medium.
20. The method of claim 16, wherein the oxygen levels in the culture are reduced and maintained by a method selected from the group consisting of limiting the flow of air, altering the amount of oxygen in the gas composition, altering the backpressure of the fermentation reactor, and altering the feed rate.
21. A method for purifying a protein from a yeast fermentation culture comprising the ordered steps of a) adjusting the pH of the fermentation medium above or below the isoelectric point of the protein to be purified; b) removing the cells from the pH adjusted fermentation medium; c) subjecting the cell-free fermentation medium to ion-exchange chromatography and eluting the protein as a solution; d) passing the eluted protein

solution through a first membrane to remove unwanted high molecular weight solutes; and e) concentrating and diafiltering the protein permeate on a second membrane to remove low molecular weight solutes.

22. The method of claim 21, wherein the pH of the eluted protein solution is optimized prior to ultrafiltration step d) to facilitate permeation of the protein through the first membrane.
23. The method of claim 22, wherein the pH of the filtered protein permeate is optimized prior to concentration step e) to facilitate flux through the second membrane.
24. The method of claim 21, wherein the protein to be purified is Type II brazzein; step a) comprises adjusting the pH of the fermentation medium to about 3.7-3.9; step b) comprises microfiltration; step c) comprises cation-exchange chromatography; the pH of the eluted protein solution is adjusted to about 6.0-6.2 prior to step d); and the Type II brazzein is recovered at greater than 95% purity.
25. The method of claim 21, wherein the protein to be purified is Type III brazzein; step a) comprises adjusting the pH of the fermentation medium to about 3.7-3.9; step b) comprises microfiltration; step c) comprises cation-exchange chromatography; the pH of the eluted protein solution is adjusted to about 6.0-6.2 prior to step d); the pH of the protein permeate is adjusted to about 3.8 - 4.2 prior to step e); and the Type III brazzein is recovered at greater than 95% purity.
26. The method of claim 20, wherein the pH adjusted fermentation medium is first pumped through a microfiltration membrane and the resulting cell-free fermentation medium is subsequently pumped to an ion-exchange column in a continuous process.




FIGURE 1A




FIGURE 1B




FIGURE 1C




Figure 2




Figure 3A

Fermentation Sample




Figure 3B

Fermentation




Figure 4A


Fermentation Sample

Figure 4B

Fermentation




Figure 5A


Fermentation Sample

Figure 5B

Fermentation

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/058996

A. CLASSIFICATION OF SUBJECT MATTER

INV. C12N15/81

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AI-LIAN ZHANG ET AL: "Recent advances on the GAP promoter derived expression system of Pichia pastoris" MOLECULAR BIOLOGY REPORTS ; AN INTERNATIONAL JOURNAL ON MOLECULAR AND CELLULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 36, no. 6, 10 September 2008 (2008-09-10), pages 1611-1619, XP019684802 ISSN: 1573-4978 page 1617; figure 2 ----- -/--	1-15, 21-26

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 January 2010

Date of mailing of the international search report

01/02/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Vollbach, Silke

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/058996

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MASUDA T ET AL: "High yield secretion of the sweet-tasting protein lysozyme from the yeast <i>Pichia pastoris</i> " PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 39, no. 1, 1 January 2005 (2005-01-01), pages 35-42, XP004680014 ISSN: 1046-5928 page 36; figure 1 -----	1-15, 21-26
X	WO 99/25835 A1 (ZENECA LTD [GB]; DRAKE CAROLINE RACHEL [GB]; OSBORN RUPERT WILLIAM [GB] 27 May 1999 (1999-05-27) page 14; example 3 -----	1-15
X	NARENDAR K KHATRI ET AL: "Oxygen-limited control of methanol uptake for improved production of a single-chain antibody fragment with recombinant <i>Pichia pastoris</i> " APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 72, no. 3, 11 March 2006 (2006-03-11) , pages 492-498, XP019422027 ISSN: 1432-0614 figures 1,4b -----	2,16-26
X	THEPPANYA CHAROENRAT ET AL: "Oxygen-limited fed-batch process: an alternative control for <i>Pichia pastoris</i> recombinant protein processes" BIOPROCESS AND BIOSYSTEMS ENGINEERING, SPRINGER, BERLIN, DE, vol. 27, no. 6, 1 October 2005 (2005-10-01), pages 399-406, XP019347364 ISSN: 1615-7605 page 404 - page 405; figure 4 -----	16-26
X	GORGENS J F ET AL: "Amino acid supplementation, controlled oxygen limitation and sequential double induction improves heterologous xylanase production by <i>Pichia stipitis</i> " FEMS YEAST RESEARCH, ELSEVIER SCIENCE, TOKYO, NL, vol. 5, no. 6-7, 1 April 2005 (2005-04-01) , pages 677-683, XP004789318 ISSN: 1567-1356 page 679 ----- -/--	16-26

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/058996

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OUYANG J ET AL: "High-level expression, purification, and characterization of porcine somatotropin in Pichia pastoris" PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 32, no. 1, 1 November 2003 (2003-11-01), pages 28-34, XP004469381 ISSN: 1046-5928 abstract page 30 -----	21-26

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2009/058996

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - ☒ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material
 - ☒ on paper
 - ☒ in electronic form
 - c. time of filing/furnishing
 - ☒ contained in the international application as filed
 - ☒ filed together with the international application in electronic form
 - ☐ furnished subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2009/058996

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-15

Expression of brazzein in yeast, the expression vector and methods which make thereof

2. claims: 16-26

Method for enhanced production of foreign proteins

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2009/058996

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9925835	A1	27-05-1999	AU 751370 B2 15-08-2002
			AU 1042399 A 07-06-1999
			CA 2307539 A1 27-05-1999
			EP 1032673 A1 06-09-2000
			JP 2001523689 T 27-11-2001